• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

AdvaMed Issues MedTech Compliance Guidance For COVID-19 Response

Article

The Advanced Medical Technology Association (AdvaMed) recently announced availability of a new “Code of Ethics Compliance Guidance Related to the COVID-19 Response.”

The Advanced Medical Technology Association (AdvaMed) recently announced availability of a new “Code of Ethics Compliance Guidance Related to the COVID-19 Response.”

“This guidance seeks to help AdvaMed members and other medical technology companies develop and implement processes that both support rapid decision-making in the context of the pandemic and mitigate any related compliance risks,” says Christopher L. White, AdvaMed COVID action team leader, chief operating officer and general counsel.

“As medtech companies supporting the public health response to COVID-19 work around the clock to produce essential medical products to help prevent, detect and treat this disease, we must continue to do all we can to help ensure patients are provided both timely and ethical access to our equipment, knowledge and trained personnel,” White says.

Development of the guidance was overseen by AdvaMed’s Global Compliance Steering Committee, with active input from over a dozen member company compliance officers.

“The guidance complements AdvaMed’s existing Code of Ethics, and addresses shared compliance concerns, experiences and best practices developed by our member companies as they respond to the COVID-19 pandemic," says White. "Key topics addressed in the guidance include ongoing contractual/legal obligations during a declared state of emergency; charitable donations including products, equipment, services, and/or financial support; volunteer activity by company personnel; virtual educational events; and other company processes."

To access the AdvaMed “Code of Ethics Compliance Guidance Related to the COVID-19 Response,” click here.

It's encouraged companies should consult legal counsel and compliance departments before entering into any arrangements described in the document.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.